Sahajanand Medical Technologies Receives DGGI Summons

Authority: DGGI, Mumbai Zonal Unit | Summons Date: October 16, 2026

Reader Takeaway: The company is cooperating with a procedural GST inquiry; management expects no material financial or operational impact.

What just happened

Sahajanand Medical Technologies has formally informed the stock exchanges that it received a summons from the Directorate General of GST Intelligence (DGGI), Mumbai Zonal Unit. The summons, issued under Section 70 of the CGST Act, 2017, was received by the company on October 23, 2026.

Why this matters

The regulatory inquiry is specifically focused on verifying books of accounts and evidence related to GST compliance. The scope pertains to reimbursements made by the company to its foreign subsidiaries specifically for clinical trials. Investors should note that the summons is an investigative step rather than a formal notice of violation at this stage.

Management Commentary

Management has explicitly communicated that they are fully cooperating with the tax authorities. The company is in the process of providing all requested documentation and information to the DGGI. The leadership team has indicated that they view this as a procedural matter and will continue to update the exchanges on any material developments.

Risks to watch

While the company has stated there is currently no material financial, operational, or business impact, any subsequent findings from the DGGI inquiry that lead to tax demands or penalties could alter the company's risk profile. Investors should monitor future exchange disclosures for further clarity on the investigation's outcome.